{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:21:26Z","timestamp":1782476486056,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Observational data suggest comparable efficacy of different advanced therapies in paediatric inflammatory bowel disease (pIBD). Cutaneous adverse effects (cAEs) of tumour necrosis factor antagonists (anti-TNF) may lead to treatment discontinuation. Identifying risk factors for these adverse effects could improve treatment sustainability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, multicentre observational study using Czech registry data. pIBD patients treated with anti-TNF, vedolizumab or ustekinumab were enroled. The primary outcome assessed was time to the onset of cAEs. The secondary outcome was time to the onset of severe cAEs. Multivariate Cox proportional hazards models with mixed effects were used with predefined clinically important confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analysed 546 treatment courses from 423 patients across four centres. cAEs were reported in 19.8% of therapy courses and were associated with female sex [hazard ratio (HR) 1.82, 95% confidence interval (CI): 1.18\u20132.81], a family history of atopic diseases (HR: 1.82, 95% CI: 1.13\u20132.91) and anti-TNF therapy (HR: 6.84, 95% CI 1.98\u201323.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrated a strong association between cAEs and anti-TNF treatment, female sex and a family history of atopic diseases. Non-anti-TNF advanced therapy may be considered early for patients at risk for cAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Cutaneous adverse effects occur in up to 20% of advanced therapy courses in paediatric inflammatory bowel disease, with approximately half being severe.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Female sex and a family history of atopic disease are associated with an increased risk of cutaneous adverse effects.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Among patients requiring a change in advanced therapy due to cutaneous adverse effects, switching to ustekinumab is associated with higher odds of resolution compared with switching to another anti-TNF agent.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Early use of non-anti-TNF agents may be considered in paediatric patients at higher risk of cutaneous adverse effects.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-05195-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:56:05Z","timestamp":1781996165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for cutaneous complications of advanced therapies in paediatric inflammatory bowel disease patients"],"prefix":"10.1038","author":[{"given":"Denis","family":"Kazeka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Zarubova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Copova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Lerchova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Karaskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Hrunka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Durilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Mitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vlckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kubat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Duskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Bronsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Hradsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"5195_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF Van Rheenen","year":"2021","unstructured":"Van Rheenen, P. F. et al. The Medical Management of Paediatric Crohn\u2019s Disease: an ECCO-ESPGHAN Guideline Update. J. Crohn\u2019s Colitis 15, 171\u2013194 (2021).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"5195_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/jpn3.70097","volume":"81","author":"E Wine","year":"2025","unstructured":"Wine, E. et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care\u2014an updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn\u2019s and Colitis Organisation. J. Pediatr. Gastroenterol. Nutr. 81, 765\u2013815 (2025).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5195_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor, N. M. et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 415\u2013427 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"5195_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","volume":"71","author":"MME Jongsma","year":"2022","unstructured":"Jongsma, M. M. E. et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: an open-label multicentre randomised controlled trial. Gut 71, 34\u201342 (2022).","journal-title":"Gut"},{"key":"5195_CR5","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200\u20132211 (2022).","journal-title":"Lancet"},{"key":"5195_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa, J. S., Olivera, P. A., Danese, S. & Peyrin-Biroulet, L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol. Hepatol. 7, 161\u2013170 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"5195_CR7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","volume":"167","author":"AN Ananthakrishnan","year":"2024","unstructured":"Ananthakrishnan, A. N. et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology 167, 1460\u20131482 (2024).","journal-title":"Gastroenterology"},{"key":"5195_CR8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Fr\u00e9ling","year":"2015","unstructured":"Fr\u00e9ling, E. et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am. J. Gastroenterol. 110, 1186\u20131196 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"5195_CR9","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ibd\/izy112","volume":"24","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S., Maltz, R. M., Boyle, B. & Kim, S. C. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm. Bowel Dis. 24, 2086\u20132092 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"5195_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000514030","volume":"237","author":"JM Moon","year":"2021","unstructured":"Moon, J. M. et al. Incidence of psoriasis in patients with inflammatory bowel disease: a nationwide population-based matched cohort study. Dermatology 237, 330\u2013337 (2021).","journal-title":"Dermatology"},{"key":"5195_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/acr.24100","volume":"73","author":"LH Buckley","year":"2021","unstructured":"Buckley, L. H., Xiao, R., Perman, M. J., Grossman, A. B. & Weiss, P. F. Psoriasis associated with tumor necrosis factor inhibitors in children with inflammatory diseases. Arthritis Care Res. 73, 215\u2013220 (2021).","journal-title":"Arthritis Care Res."},{"key":"5195_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","volume":"56","author":"ME Sherlock","year":"2013","unstructured":"Sherlock, M. E. et al. Infliximab-induced psoriasis and Psoriasiform skin lesions in pediatric crohn disease and a potential association with IL-23 receptor polymorphisms. J. Pediatr. Gastroenterol. Nutr. 56, 512\u2013518 (2013).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5195_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","volume":"20","author":"T M\u00e4lk\u00f6nen","year":"2014","unstructured":"M\u00e4lk\u00f6nen, T. et al. Skin reactions during anti-TNF\u03b1 therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm. Bowel Dis. 20, 1309\u20131315 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"5195_CR14","unstructured":"Ruemmele, F. & Pigneur, B. Is there a correlation between anti-tumor necrosis factor trough levels and the occurrence of paradoxical cutaneous and articular manifestations in children with inflammatory bowel disease (IBD)? J. Pediatr. Gastroenterol. Nutr. 63, S76 (2016)."},{"key":"5195_CR15","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1093\/ecco-jcc\/jjy222.471","volume":"13","author":"G Veereman","year":"2019","unstructured":"Veereman, G. et al. P347 New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience. J. Crohn\u2019s Colitis 13, S276\u2013S277 (2019).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"5195_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ced\/llae432","volume":"50","author":"D Hilewitz","year":"2025","unstructured":"Hilewitz, D. et al. Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-\u03b1 inhibitors. Clin. Exp. Dermatol. 50, 558\u2013563 (2025).","journal-title":"Clin. Exp. Dermatol."},{"key":"5195_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1203475420917387","volume":"24","author":"M-L Cossio","year":"2020","unstructured":"Cossio, M.-L. et al. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J. Cutan. Med. Surg. 24, 333\u2013339 (2020).","journal-title":"J. Cutan. Med. Surg."},{"key":"5195_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1365-2133.2007.08183.x","volume":"157","author":"CL Thomas","year":"2007","unstructured":"Thomas, C. L. & Finlay, A. Y. The \u2018handprint\u2019 approximates to 1% of the total body surface area whereas the \u2018palm minus the fingers\u2019 does not. Br. J. Dermatol. 157, 1080\u20131081 (2007).","journal-title":"Br. J. Dermatol."},{"key":"5195_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay, A. Y. & Khan, G. K. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","journal-title":"Clin. Exp. Dermatol."},{"key":"5195_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"2010","unstructured":"Lewis-Jones, M. S. & Finlay, A. Y. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br. J. Dermatol. 132, 942\u2013949 (2010).","journal-title":"Br. J. Dermatol."},{"key":"5195_CR21","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00431-021-04077-0","volume":"180","author":"O Hradsky","year":"2021","unstructured":"Hradsky, O. et al. Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn\u2019s disease. Eur. J. Pediatr. 180, 3001\u20133008 (2021).","journal-title":"Eur. J. Pediatr."},{"key":"5195_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/jpn3.12066","volume":"78","author":"K Van Hoeve","year":"2024","unstructured":"Van Hoeve, K., Thomas, D., Hillary, T., Hoffman, I. & Dreesen, E. Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 78, 95\u2013104 (2024).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5195_CR23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3899\/jrheum.211359","volume":"49","author":"K Baggett","year":"2022","unstructured":"Baggett, K. et al. Incidence rates of psoriasis in children with inflammatory bowel disease and juvenile arthritis treated with tumor necrosis factor inhibitors and disease-modifying antirheumatic drugs. J. Rheumatol. 49, 935\u2013941 (2022).","journal-title":"J. Rheumatol."},{"key":"5195_CR24","doi-asserted-by":"publisher","first-page":"847160","DOI":"10.3389\/fimmu.2022.847160","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie, W., Xiao, S., Huang, H. & Zhang, Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front. Immunol. 13, 847160 (2022).","journal-title":"Front. Immunol."},{"key":"5195_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.18106","volume":"60","author":"RLM Nordestgaard","year":"2024","unstructured":"Nordestgaard, R. L. M. et al. Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent\u2014results from a Danish nationwide cohort study, 2000\u20132018. Aliment. Pharmacol. Ther. 60, 457\u2013468 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"5195_CR26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/MIB.0000000000000342","volume":"21","author":"JS Soh","year":"2015","unstructured":"Soh, J. S. et al. Concomitant use of azathioprine\/6-mercaptopurine decreases the risk of anti-TNF\u2013induced skin lesions. Inflamm. Bowel Dis. 21, 832\u2013839 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"5195_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/2475530318810851","volume":"4","author":"SJ Li","year":"2019","unstructured":"Li, S. J., Perez-Chada, L. M. & Merola, J. F. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J. Psoriasis Psoriatic Arthritis 4, 70\u201380 (2019).","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"5195_CR28","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/imj.15859","volume":"53","author":"M Au","year":"2023","unstructured":"Au, M. et al. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm. Intern. Med. J. 53, 1854\u20131865 (2023).","journal-title":"Intern. Med. J."},{"key":"5195_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon, H. et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J. Crohn\u2019s Colitis 18, 1\u201337 (2024).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"5195_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","volume":"16","author":"MT Dolinger","year":"2022","unstructured":"Dolinger, M. T. et al. Outcomes of children with inflammatory bowel disease who develop anti-tumour necrosis factor-induced skin reactions. J. Crohn\u2019s Colitis 16, 1420\u20131427 (2022).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"5195_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","volume":"22","author":"C Olbj\u00f8rn","year":"2020","unstructured":"Olbj\u00f8rn, C., Rove, J. B. & Jahnsen, J. Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature. Pediatr. Drugs 22, 409\u2013416 (2020).","journal-title":"Pediatr. Drugs"},{"key":"5195_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/medicina60010106","volume":"60","author":"A Olteanu","year":"2024","unstructured":"Olteanu, A. et al. Paradoxical psoriasis induced by ustekinumab: a comprehensive review and case report. Medicina 60, 106 (2024).","journal-title":"Medicina"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05195-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05195-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:56:06Z","timestamp":1781996166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05195-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":32,"alternative-id":["5195"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05195-x","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.K.: lecture\/workshop fee: Takeda, Vitabalans Oy. K.Z.: consultancy: Nestl\u00e9. I.C.: nothing to disclose. T.L.: nothing to disclose. J.S.: lectures\/Congress fees\/consultancy: MSD, AbbVie, Takeda, Nutricia, Nestl\u00e9. E.K.: nothing to disclose. M.H.: lectures\/Congress fees\/consultancy: Nutricia, Nestl\u00e9. K.M.: reports lectures, consultation fees: AbbVie, Eli Lilly, Johnson&Johnson, Takeda. M.D.: Congress fees: Nutricia. E.V.: workshop\/Congress fee: Biocodex, Ewopharma. M.K.: nothing to disclose. J.D.: nothing to disclose. J.B.: lectures\/Congress fees\/consultancy: AbbVie, Nutricia, Nestl\u00e9, Sanofi, Pfizer, Vitabalans. O.H.: lectures\/Congress fees\/consultancy: MSD, AbbVie, Takeda, Nutricia, Sandoz, Eli Lilly, Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from legal guardians. Approval was granted by the Ethics Committee of all the participating centres.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}]}}